非选择性β—受体阻滞剂对失代偿肝硬化患者循环及肾损伤的影响研究(5)
[14]Kamath PS,Kim WR. Advanced liver disease study group. The model for end-stage liver disease(MELD)[J].Hepatology,2007,45(3):797-805.
[15]Child CG,Turcotte JG. Surgery and portal hypertension[J].Major Problems in Clinical Surgery,1964,1(1):1-85.
[16]Sersté T,Francoz C,Durand F,et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites:A cross-over study[J].Journal of Hepatology,2011,55(4):794-799.
[17]Robins A,Bowden A,Watson W,et al. Propranolol at modest doses does not impair survival in patients with cirrhosis and refractory ascites[J]. Hepatology,2013,71(4):448-457.
[18]Baares R,Moitinho E,Matilla A,et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J]. Hepatology, 2002,36(6):1367-1373.
[19]Reiberger T,Ulbrich G,Ferlitsch A,et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J].Gut, 2013, 62(11):1634-1641.
[20]Efe C,Purnak T,Ozaslan E. The deleterious effects of propranolol on patients with cirrhosis[J]. Hepatology,2011, 53(1):371-372.
[21]Krag A,Bendtsen F,Mller S. Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites[J]. Hepatology,2011,53(1):370-371.
(收稿日期:2018-02-07), 百拇医药(武瑞 刘春涛 傅晓晴)
[15]Child CG,Turcotte JG. Surgery and portal hypertension[J].Major Problems in Clinical Surgery,1964,1(1):1-85.
[16]Sersté T,Francoz C,Durand F,et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites:A cross-over study[J].Journal of Hepatology,2011,55(4):794-799.
[17]Robins A,Bowden A,Watson W,et al. Propranolol at modest doses does not impair survival in patients with cirrhosis and refractory ascites[J]. Hepatology,2013,71(4):448-457.
[18]Baares R,Moitinho E,Matilla A,et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J]. Hepatology, 2002,36(6):1367-1373.
[19]Reiberger T,Ulbrich G,Ferlitsch A,et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J].Gut, 2013, 62(11):1634-1641.
[20]Efe C,Purnak T,Ozaslan E. The deleterious effects of propranolol on patients with cirrhosis[J]. Hepatology,2011, 53(1):371-372.
[21]Krag A,Bendtsen F,Mller S. Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites[J]. Hepatology,2011,53(1):370-371.
(收稿日期:2018-02-07), 百拇医药(武瑞 刘春涛 傅晓晴)